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O B J E C T I V E S The purpose of this study was to analyze the effects of left ventricular assist devices
(LVADs) on myocardial sympathetic innervation of the failing heart.
B A C KG ROUND Ventricular unloading by LVADs seems to cause reverse remodeling of the failing
heart, but little is known about the sympathetic nerve activity during long-term mechanical unloading.
METHOD S We studied the effects of LVADs on myocardial sympathetic innervation, by iodine
123-meta-iodobenzylguanidine (123I-mIBG) scintigraphy performed before and 3 months after LVAD
implantation in 12 end-stage heart failure patients. We calculated the: 1) heart-to-mediastinum (H/M)
uptake ratio on early and delayed images, indicating myocardial accumulation of 123I-mIBG; and 2) rate
of 123I-mIBG washout after initial accumulation. Similar 123I-mIBG imaging and functional and hemo-
dynamic measurements were made 3 months apart in 6 other heart failure patients not treated with
an LVAD.
R E S U L T S After 3months of LVAD support, themean left ventricular ejection fraction had increased from
19  6% to 29  9% (p  0.006), peak oxygen consumption increased from 9  4 ml/kg/min to 13  3
ml/kg/min (p 0.058), serum sodium increased from 135 4 mEq/l to 140 2 mEq/l (p 0.014), whereas
the left ventricular end-diastolic diameter decreased from 72 7 mm to 56 3 mm (p 0.002), pulmonary
capillary wedge pressure decreased from 30  6 mm Hg to 5  3 mm Hg (p  0.012), serum creatinine
decreased from 1.5 0.6mg/dl to 1.0 0.4mg/dl (p 0.011), and B-type natriuretic peptide decreased from
2,279  1,900 pg/ml to 102  5 pg/ml (p  0.003). After 3 months of LVAD, the H/M ratio increased on
delayed images from 1.25 0.18 to 1.43 0.13 (p 0.01) and on early images from 1.35 0.19 to 1.44
0.11 (p 0.028), and the washout rate decreased from 51.0 23.2% to 30.6 8.7%, (p 0.015). There was
a signiﬁcant correlation between the late H/MmIBG ratio and B-type natriuretic peptide (R 0.77, p 0.01)
and systolic pulmonary pressure (R 0.7, p 0.05). No signiﬁcant scintigraphic, functional or hemodynamic
change was observed between the 2 evaluations in the 6 patients not treated with an LVAD.
CONC L U S I O N S Ventricular unloading caused clinical, functional, and hemodynamic improve-
ments accompanied by improvements in sympathetic innervation in the failing heart. (J Am Coll
Cardiol Img 2010;3:64–70) © 2010 by the American College of Cardiology Foundation
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65echanical circulatory support with left
ventricular assist devices (LVADs) has
become a standard bridge to cardiac
transplantation (1) and has also been
pproved as destination therapy for selected patients
resenting with end-stage heart failure (HF) (2).
linical applications of LVAD have shown that it
ight reverse the complex process of chronic left
entricular (LV) remodeling to a degree where a
ubset of patients can be weaned from the device
See page 71
fter the return of essential cardiac function (3–6).
pecifically, LVAD profoundly unloads LV vol-
mes and pressures, reversing the compensatory and
tress responses of the overloaded myocardium and
ausing its structural and functional reverse remod-
ling. The mechanisms that facilitate the process of
everse remodeling have recently become the object
f intensive research.
Sympathetic innervation has been inversely cor-
elated with cardiac function with patients with
hronic HF (7,8). A reduced myocardial accumu-
ation of iodine 123-meta-iodobenzylguanidine
123I-mIBG) has been correlated with myocardial
orepinephrine concentrations (9), myocardial cell
njury (10), and adverse prognosis of patients with
F (7). However, little is known about sympathetic
nnervation during long-term unloading with an
VAD (11).
This study examined the effects of LVAD-
nduced unloading on cardiac function, structure,
nd hemodynamics and myocardial sympathetic
nnervation evaluated by 123I-mIBG myocardial
cintigraphy in patients with end-stage HF.
E T H O D S
atient population. Consecutive HF patients who
equired LVAD implantation due to progressive de-
erioration because of their syndrome were included in
he study. These patients were followed long term in
ur HF program, and the investigators were highly
amiliar with the natural history of their HF syn-
rome. Important baseline demographic, clinical, he-
odynamic, and laboratory characteristics of each
atient are shown in Table 1. All patients were in New
ork Heart Association HF functional class IV and
efractory to optimal medical therapy. Four patients
ad diabetes (2 insulin dependent and 2 insulin
ondependent). After LVAD implantation, all pa-
ients were treated with standard doses of a beta- bdrenergic blocker, renin-angiotensin axis inhibitors,
pironolactone, and digoxin. The LVADs used were
eartMate XVE in 2 patients, and HeartMate II
Thoratec Corporation, Pleasanton, California) in 10
atients. The HeartMate XVE was set to auto mode
or optimal ventricular unloading, and the HeartMate
I was fixed between 9,000 and 11,000 rpm, to reach
pulsatility index (estimated by the device’s software)
etween 3 and 4.
At the time of enrollment in the study, the patients
nderwent echocardiography, Naughton protocol
readmill cardiopulmonary exercise stress testing to
easure peak oxygen consumption, and right heart
atheterization. These tests were repeated at 3 months
fter LVAD implantation when the patients had
ompletely recovered from the surgical procedure and
ere fully active.
Patients with advanced chronic HF, LV systolic
ysfunction, and an ejection fraction 30%, un-
reated with LVAD were also included in our study
f they fulfilled the criterion of being optimally
reated medically for 6 months. These
atients were randomly chosen from the
opulation followed in a long-term HF
rogram. They underwent the same gen-
ral evaluation (myocardial scintigraphy
nd functional and hemodynamic evalua-
ions), were followed for a similar period
f observations, and were treated with the
ame HF medications as the LVAD pa-
ients (standard doses of beta-adrenergic
lockers, renin-angiotensin system inhib-
tors, spironolactone, and digoxin).
23I-mIBG imaging. Baseline 123I-mIBG imaging was
erformed in the fasting state, after withholding all
edications on the morning of examination. Planar
nterior images of the chest were obtained 1 h (early
mages) and 4 h (late images) after the intravenous
njection of 111 to 148 MBq of 123I-mIBG. All scans
ere acquired with a single-headed, tomographic
ophycamera DS7 digital gamma camera (Sopha
edical Vision International, Buc, France), with a
56  256 matrix on a dedicated Sophy NXT
omputer system (Sopha Medical Vision Interna-
ional) equipped with a low-energy, all-purpose,
arallel-hole collimator using a 20% window centered
n the 159-keV peak. Myocardial 123I-mIBG activity
as measured in a manually outlined region of interest
urrounding the heart, excluding the ventricular blood
ool, to standardize the cardiac uptake. A 20 15-pixel
egion of interest was also drawn over the upper
ediastinum. The regions of interest were analyzed
A B B
A N D
HF
H/M
LV
LVAD
device
mIBG
iodoby a nuclear medicine expert unaware of thR E V I A T I O N S
A C R O N YM S
heart failure
heart-to-mediastinum
left ventricular
 left ventricular assist
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66ients’ clinical information. The heart/mediastinum
H/M) uptake ratio in early (H/M early) and late
H/M late) images was calculated, without back-
round subtraction, as mean counts/pixel in the
ardiac region of interest, divided by mean counts/
ixel in the upper mediastinal region of interest.
tatistical analysis. The data are expressed as mean 
D. The nonparametric Wilcoxon signed-rank test
as used to assess the statistical significance of
ifferences observed at consecutive time points.
orrelations among the various variables were eval-
ated using Pearson’s correlation coefficient. The
onparametric Spearman’s correlation coefficient
as used to assess associations of B-type natriuretic
eptide changes with other parameters. The thresh-
ld of significance was set at p  0.05. Statistical
nalysis was performed using the SPSS version 15.0
oftware (SPSS, Chicago, Illinois).
The study protocol was approved by our institu-
ional review board, and after they had granted their
nformed consent, the patients were followed
rospectively.
E S U L T S
23I-mIBG observations. After 3 months of LVAD
upport, H/M early increased from 1.35  0.19 to
.44  0.11 (p  0.028) and H/M late from 1.25 
.18 to 1.43  0.13 (p  0.01) (Fig. 1). Further-
ore, the washout rate significantly decreased from
1.0  23.2% to 30.6  8.7% (p  0.015) (Fig. 2).
n Figure 3, we show the observed improvement in
/M late in 1 of our patients (Patient #5 in Table
). The abnormalities in baseline H/M early and
ashout rates in 6 patients with ischemic heart
isease versus 6 patients with nonischemic heart
isease were similar. However, after 3 months of
VAD support, the increase in H/M late among
atients with nonischemic heart disease (0.23 
.15) was more than twice that observed among
atients with ischemic heart disease (0.10  0.14),
difference that did not reach statistical signifi-
ance, probably because of the small study sample.
unctional, structural, hemodynamic, and biochemical
hanges at 3 months. At 3 months of follow-up,
chocardiographic, hemodynamic, functional, and
iochemical changes were observed that were consis-
ent with a significant improvement in clinical status
Table 2). A moderately strong correlation was found
etween the changes in H/M late and B-type natri-
retic peptide (R  0.77, p  0.01) and systolic
ulmonary artery pressure (R  0.7, p  0.05).Furthermore, a moderately strong correlation wasT
P *I N
f
p
p
O
6
L
m
g
s
c
D
I
t
s
i
r
m
r
c
p
r
c
e
w
f
r
o
f
d
l
c
i
t
d
(
b
s
c
a
u
o
a
o
c
i
(
i
r
e
n
i
s
r
b
i
i
f
i
o
t
f
1
e
c
d
f
i
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 3 , N O . 1 , 2 0 1 0
J A N U A R Y 2 0 1 0 : 6 4 – 7 0
Drakos et al.
Myocardial Sympathetic Innervation and LVAD
67ound between changes in systolic pulmonary artery
ressure and H/M early and washout rate (R  0.7,
 0.04 for both correlations).
bservations in patients not treated with LVAD. In the
patients with HF who were not treated with an
VAD, a significant difference between baseline and 3
onths was observed in neither the mIBG scinti-
raphic uptake nor their functional or hemodynamic
tatus. However, the filling pressures tended to de-
rease between baseline and 3 months (Table 3).
I S C U S S I O N
n this study, LV unloading by an LVAD improved
he sympathetic innervation of the failing heart as-
essed by 123I-mIBG myocardial scintigraphy. Specif-
cally, after 3 months of LVAD support, the H/M
atio on delayed images and the washout rate, the
ost important indicators of sympathetic innervation
evealed by 123I-mIBG imaging, were both signifi-
antly improved.
LVAD profoundly unloads the LV volumes and
ressures, which reverses the compensatory and stress
esponses of the overloaded myocardium and might
ause enough structural and functional reverse remod-
ling of the heart to allow a subset of patients to be
eaned from the device after restoration of cardiac
unction (3–6). The mechanisms by which this reverse
emodeling and eventually recovery occur are an area
f active research, with the aim of identifying the
actors associated with a sustained functional myocar-
ial recovery (12). In several studies, mechanical un-
oading of the heart with an LVAD caused significant
hanges in a wide variety of biomarkers (13). Specif-
cally, with regard to myocardial adrenergic innerva-
ion, long-term mechanical unloading restored the
ensity of beta-adrenergic receptors in cardiomyocytes
14), normalized the distribution of the myocardial
eta-adrenergic receptors (15), and enhanced the re-
ponse to beta-adrenergic stimulation (16). A signifi-
ant increase in the mRNA expression of the beta2-
drenergic receptor has also been observed in the
nloaded failing rat heart (17).
123I-mIBG imaging is useful to grade the severity
f HF and estimate its prognosis. Specifically, an
ccelerated washout rate and a decreased H/M ratio
n delayed 123I-mIBG images have both been
orrelated with LV dysfunction in patients present-
ng with HF, regardless of the underlying disease
7,8,18). Furthermore, the H/M ratio on delayed
mages and the washout rate have been widely
ecognized as reliable predictors of adverse cardiac
vents in patients with HF due to ischemic oronischemic heart disease (7,19–24). Finally and
mportantly, comparative 123I-mIBG scintigraphic
tudies obtained before and during treatment with
enin-angiotensin axis inhibitors, beta-adrenergic
lockers, or spironolactone showed an improvement
n the washout rate and the H/M ratio on delayed
mages, associated with an improvement in cardiac
unction, indicating the contribution of this technique
n the evaluation of therapeutic effects (8,25–28). This
bservation might have important implications, par-
icularly for LVAD recipients whose native cardiac
unction is difficult to evaluate. Improvements in the
23I-mIBG images could be used to identify respond-
rs to LVAD-induced unloading who might become
andidates for explantation of the device after the
evelopment of a potentially sustained myocardial
unctional recovery.
To our knowledge this is the first study reporting
mprovement of myocardial sympathetic nervous ac-
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p=0.01
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H
/M
 L
at
e
Figure 1. Effect of an LVAD on H/M Late Image
Changes in mean  SD and individual heart-to-mediastinum (H/M)
late images between baseline (Pre Op) and 3 months of left ventric
assist device (LVAD) support.
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Figure 2. Effect of an LVAD on the Washout Ratio
Changes in mean  SD and individual washout ratios between bas± 0.13
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ular9%
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(Pre Op) and 3 months of LVAD support. Abbreviations as in Figure 1.
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68ivity during chronic mechanical unloading. Miya-
awa et al. (11) observed no improvement in sympa-
hetic nerve function, evaluated by 123I-mIBG
cintigraphy, after 2 months of LV support. How-
ver, the investigators noted that none of the 10
atients included in their study had evidence of cardiac
unctional or histological recovery during LVAD sup-
ort, which they attributed to an incomplete mechan-
cal unloading by left atrial drainage-type assist devices
Figure 3. Effect of an LVAD on H/M Late Image
H/M uptake ratio in late image at baseline (Pre LVAD, zoom factor
1,2), Patient #5 in Table 1. Abbreviations as in Figure 1.
3-Month Clinical, Functional, Hemodynamic, and Biochemical
Study Sample
Baseline 3 Months* p Value
80 11 66.7 10.3 0.016
pressure (mm Hg)
90 8 89 11 NS
62 8 81 10 0.005
s (mm Hg)
12 5 3.4 1.8 0.012
tolic 57 14 30 7 0.028
38 6 15 5 0.018
30 6 5 3 0.012
1.7 0.3 2.9 0.8 0.012
3.2 0.9 2.075 1.0 0.041
72 7 56 3 0.002
19 6 29 9 0.006
iastolic thickness (mm) 8.2 1.0 8.5 0.9 0.196
EDD (mm) 8.7 1.1 8.8 0.9 0.680
1,510/877/3,535† 83/53/150† 0.003
76 26 51 23 0.028
) 1.5 0.6 1.0 0.4 0.011
nless indicated otherwise. *Echocardiographic, hemodynamic, and exercise
ed with the LV assist device functioning at full support. †Values represent
3, respectively.pen; NS  not signiﬁcant; other abbreviations as in Table 1.n the majority of patients. In contrast, in our study,
he marked improvement in various functional, mor-
hological, and biochemical characteristics observed
fter effective chronic mechanical unloading with the
eartMate XVE and II devices was accompanied by
ignificant improvements in sympathetic innervation.
he results of these 2 studies suggest that responders
o LVAD-induced unloading can be identified by
valuating the functional recovery of the native heart
ith 123I-mIBG imaging. The recovery of myocardial
ympathetic innervation may be an important factor in
he functional recovery of the myocardium during
VAD support, and 123I-mIBG imaging might be
sed to evaluate the reverse remodeling that occurs
uring long-term mechanical unloading of the native
eart. The correlation that we observed between
cintigraphic improvements and changes in blood
oncentrations of B-type natriuretic peptide or
hanges in pulmonary artery pressures supports this
ypothesis. The lowering of B-type natriuretic peptide
lood concentrations is consistent with the suppres-
ion of adverse neurohormonal activation. Further-
ore, increased filling pressures have been associated
ith adverse progression of remodeling (29–31).
tudy limitations. The limitations of this study in-
lude the small number of patients studied and the
act that the follow-up period was relatively short.
urthermore, the hemodynamic and echocardio-
raphic data provided were obtained during full
VAD support and may not represent the native’s
eart functional performance during increased pres-
ure and volume-loading conditions. Another limita-
ion is the fact that the patients were not on exactly the
ame medical regimen before and after LVAD im-
and after 3 months of LVAD support (Post LVAD, zoom factor1)Table 2. Baseline and
Characteristics of the
Heart rate (beats/min)
Systemic arterial blood
Systolic
Diastolic
Central blood pressure
Mean RA
Right ventricular sys
Mean PA
PCW
CI (l/m2/min)
PVR (WU)
LV
EDD (mm)
EF (%)
Posterior wall end-d
Interventricular septum
BNP (pg/ml)
Serum BUN (mg/dl)
Serum creatinine (mg%
Values are mean  SD u
capacity data were obtain
median/quartile 1/quartilelantation. However, the included patients were on
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69he same classes of antiremodeling medications (beta-
lockers and renin-angiotensin-aldosterone axis in-
ibitors) before and after LVAD therapy with the
xception of 4 patients who were not administered
eta-blockers and 2 patients who were not adminis-
ered spironolactone in the pre-LVAD implantation
eriod but received these agents post-implantation. In
ddition, in 1 of the included patients, no beta-blocker
as administered, either before or after LVAD im-
lantation, due to bradyarrhythmia. Noteworthy,
owever, in these particular patients, our 123I-mIBG
nd functional findings were not different compared
ith the rest of the study patients.
O N C L U S I O N S
VAD-induced ventricular unloading caused clinical
nd hemodynamic improvements that were associated
ith improvements in the sympathetic innervation of
ailing hearts. Most importantly, the improvement in
ympathetic innervation needs to be prospectively
xplored, with a view to identifying potential predic-
ors of sustained functional myocardial recovery dur-
ng or even before LVAD therapy.
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